Pediatrics Efficacy and Safety of Naltrexone Use in Pediatric Patients with Autistic Disorder
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Objective: To review the efficacy and safety of naltrexone in pediatric patients with autistic disorder (AD). Data Sources: Using the terms pediatric, child, naltrexone, autism, and autistic disorder, a literature search was performed using MEDLINE (1966–May 18, 2006) and the International Pharmaceutical Abstracts (1971–May 18, 2006) database. The references of these articles were scanned for additional relevant literature. Study Selection and Data Extraction: All articles describing or evaluating the efficacy and/or safety of naltrexone in pediatric patients with AD were included in this review. Three case reports, 8 case series, and 14 clinical studies were identified as pertinent. Data Synthesis: Naltrexone has been used most commonly at doses ranging from 0.5 to 2 mg/kg/day and found to be predominantly effective in decreasing self-injurious behavior. Naltrexone may also attenuate hyperactivity, agitation, irritability, temper tantrums, social withdrawal, and stereotyped behaviors. Patients may also exhibit improved attention and eye contact. Transient sedation was the most commonly reported adverse event. Small sample size, short duration, and inconsistent evaluative methods characterize the available research. Conclusions: A child affected by AD may benefit from a trial of naltrexone therapy, particularly if the child exhibits self-injurious behavior and other attempted therapies have failed. Serious adverse effects have not been reported in short-term studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Autism in a US Metropolitan Area
Yeargin-Allsopp, M., Rice, C., Karapurkar, T., Doernberg, N., Boyle, C., & Murphy, C. (2003) · JAMA · doi:10.1001/jama.289.1.49 · Cited by 1,248
The epidemiology of autism: a review
FOMBONNE, E. (1999) · Psychological Medicine · doi:10.1017/s0033291799008508 · Cited by 981
The UCLA-University of Utah epidemiologic survey of autism: prevalence
(1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.2.194 · Cited by 273
Naltrexone in autistic children: Behavioral symptoms and attentional learning
CAMPBELL, M., ANDERSON, L. T., SMALL, A. M., ADAMS, P., GONZALEZ, N. M., & ERNST, M. (1993) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199311000-00024 · Cited by 210
A prevalence study of pervasive developmental disorders in North Dakota.
BURD, L., FISHER, W., & KERBESHIAN, J. (1987) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-198709000-00014 · Cited by 150
Brief report: A double-blind study of naltrexone in infantile autism
Leboyer, M., Bouvard, M. P., Launay, J.-M., Tabuteau, F., Waller, D., Dugas, M., Kerdelhue, B., Lensing, P., & Panksepp, J. (1992) · Journal of Autism and Developmental Disorders · doi:10.1007/bf01058158 · Cited by 130
Bouvard, M. P., Leboyer, M., Launay, J.-M., Recasens, C., Plumet, M.-H., Waller-Perotte, D., Tabuteau, F., Bondoux, D., Dugas, M., Lensing, P., et al. (1995) · Psychiatry Research · doi:10.1016/0165-1781(95)02601-r · Cited by 112
Naltrexone in autistic children: An acute open dose range tolerance trial
CAMPBELL, M., OVERALL, J. E., SMALL, A. M., SOKOL, M. S., SPENCER, E. K., ADAMS, P., FOLTZ, R. L., MONTI, K. M., PERRY, R., NOBLER, M., et al. (1989) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-198903000-00009 · Cited by 93
Research works printed but not linked: 30
- First MB, ed. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000.
- 10.1097/00004703-199510000-00002 · DOI
- 10.1542/peds.108.5.1155 · DOI · Paper page
- 10.1542/peds.2004-1958 · DOI · Paper page
- 10.1177/088307380401900301.155 · DOI · Paper page
- McDougle CJ, Stigler KA, Posey DJ. Treatment of aggression in children and adolescents with autism and conduct disorder. J Clin Psychiatry 2003;64(suppl 4): 16–25.
- 10.1016/0166-2236(79)90071-7 · DOI · Paper page
- 10.1002/ana.410220419 · DOI · Paper page
- 10.1016/S0140-6736(88)91525-5 · DOI
- Campbell M, Adams P, Small AM, Tesch LM, Cunen EL. Naltrexone in infantile autism. Psychopharmacol Bull 1988;24:135–9.
- 10.1159/000480957 · DOI
- Barrett RP, Feinstein C, Hole WT. Effects of naloxone and naltrexone on self-injury: a double-blind, placebo-controlled analysis. Am J Ment Retard 1989;93:644–51.
- 10.1007/BF02284716 · DOI
- 10.1007/BF02284764 · DOI
- Lensing P, Klingler D, Lampi C., Naltrexone open trial with a 5-year-old-boy. A social rebound reaction. Acta Paedopsychiatr 1992; 55:169–73.
- Akkok F. The effects of naltrexone in autistic children: report of two cases. Turk J Pediatr 1995;37:19–23.
- 10.1023/A:1005674016014 · DOI · Paper page
- Campbell M, Anderson LT, Small AM, Locascio JJ, Lynch NS, Chorocco MC. Naltrexone in autistic children: a double-blind and placebo-controlled study. Psychopharmacol Bull 1990;26:130–5.
- Ernst M, Devi L, Silva RR, . Plasma beta-endorphin levels, naltrexone, and haloperidol in autistic children. Psychopharmacol Bull 1993;29:221–7.
- Gonzalez NM, Campbell M, Small AM, . Naltrexone plasma levels, clinical response and effect on weight in autistic children. Psychopharmacol Bull 1994;30:203–8.
- 10.1016/0165-1781(95)02749-M · DOI
- 10.1097/00004583-199502000-00018 · DOI
- 10.1016/0006-3223(95)00297-9 · DOI
- Scifo R, Cioni M, Nicolosi A., Opioid-immune interactions in autism: behavioural and immunological assessment during a doubleblind treatment with naltrexone. Ann Ist Super Sanita 1996;32:351–9.
- Kolmen BK, Feldman HM, Handen BL, Janosky JE. Naltrexone in young autistic children: replication study and learning measures. J Am Acad Child Adolesc Psychiatry 1997;36:1570–8.
- 10.1016/S0924-977X(99)00010-3 · DOI
- 10.1097/00004583-199905000-00021 · DOI
- 10.1023/A:1023000929040 · DOI
- 10.1097/00004583-199808000-00006 · DOI
- 10.1177/106002809703101102 · DOI
Cited by
Leekam, S. R., Prior, M. R., & Uljarevic, M. (2011) · Psychological Bulletin · doi:10.1037/a0023341 · Cited by 612
Systematic review of tools to measure outcomes for young children with autism spectrum disorder
McConachie, H., Parr, J. R., Glod, M., Hanratty, J., Livingstone, N., Oono, I. P., Robalino, S., Baird, G., Beresford, B., Charman, T., et al. (2015) · Health Technology Assessment · doi:10.3310/hta19410 · Cited by 373
Autism Spectrum Disorder and Substance Use Disorder
Kunreuther, E. (2020) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2020.03.002 · Cited by 333
Whiteley, P., Haracopos, D., Knivsberg, A.-M., Reichelt, K. L., Parlar, S., Jacobsen, J., Seim, A., Pedersen, L., Schondel, M., & Shattock, P. (2010) · Nutritional Neuroscience · doi:10.1179/147683010x12611460763922 · Cited by 266
Current Enlightenment About Etiology and Pharmacological Treatment of Autism Spectrum Disorder
Eissa, N., Al-Houqani, M., Sadeq, A., Ojha, S. K., Sasse, A., & Sadek, B. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00304 · Cited by 260
Metadata
- Authors
- Eichaar, G. M., Maisch, N. M., Augusto, L. M. G., & Wehring, H. J.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2006-06
- Volume
- 40
- Issue
- 6
- Pages
- 1086-1095
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2102096940
- Cited by
- 73
- References
- 8
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.